glp-1 therapy in newport beach ca | Medical Weight Loss Best Medical Weight Loss Clinics

A GLP-1 booster is not a drug and is not a GLP-1 receptor agonist, such as medications used for type 2 diabetes

In a Phase 3 trial, orforglipron demonstrated a reduction in HbA1c levels by up to 1.6% and an average weight loss of 16 pounds over 40 weeks

Patients should avoid self-prescribing or relying on unverified online sources for peptide therapies

A multidisciplinary approach and shared decision-making remain key to balancing the benefits of these therapies with their potential risks during the perioperative period

Wegovy is approved for use in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition